Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
November 17, 2023 16:30 ET
|
Passage Bio
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
November 13, 2023 07:00 ET
|
Passage Bio
On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with...
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
October 30, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2023 16:30 ET
|
Passage Bio
PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
September 25, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
August 07, 2023 07:15 ET
|
Passage Bio
Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF...
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
August 07, 2023 07:00 ET
|
Passage Bio
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...
Passage Bio to Participate in Upcoming Investor Conferences
August 01, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
July 31, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system...